Sign up
Pharma Capital

Faron Pharma to take Clevegen cancer candidate into the clinic this year

Markku Jalkanen, chief executive of Faron Pharmaceuticals Ltd (LON:FARN), spoke to Proactive's Andrew Scott following the release of their interim results.

He says he's looking forward to kicking off the first in-human trial of the firm’s Clevegen cancer candidate later this year.

Clevegen is one of a new generation of drugs that helps to weaken a tumour’s ability to suppress the human immune system.

The focus on oncology comes after disappointing Phase III top-line data from their lead drug, Traumakine for the condition called acute respiratory distress.


View full FARN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.